Furthermore, we demonstrated that fully functional CD4FOXP3 T cells can be generated from T cells of IPEX patients (87), regardless of the underlying FOXP3 mutation and co-expression of mutated protein, thus demonstrating the feasibility of our approach and paving the way for the development of alternative therapies based on the adoptive transfer of autologous genetically modified Treg-like cells for the control of autoimmunity in IPEX syndrome. This evidence concerns the gene FOXP3 and immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome.